معرفی
Erna van 't Hag is an active researcher specializing in psychosis and schizophrenia studies, with significant contributions to the fields of cognitive behavioral therapy, virtual reality interventions, and neuroinflammation research. Her work focuses primarily on innovative treatment approaches for psychotic disorders, particularly through technology-enhanced therapeutic methods.
Her research interests center around understanding psychosis through multiple lenses. She investigates cognitive subgroups within first-episode psychosis populations, develops virtual reality applications for treating paranoid delusions, and explores novel pharmacological approaches including antiviral treatments for schizophrenia. Her work demonstrates a strong commitment to improving clinical outcomes through evidence-based, innovative interventions that bridge traditional therapy with technological advancements.
Analysis of her publication trends reveals a clear trajectory toward integrating technology with traditional psychiatric treatments. Her recent work emphasizes data harmonization across international psychosis cohorts and developing virtual reality platforms for cognitive behavioral therapy. These publications show her growing focus on collaborative, large-scale research approaches to address complex challenges in psychosis treatment.
Her scientific contributions have appeared in high-impact psychiatry journals including Schizophrenia Bulletin, Psychological Medicine, and BMC Psychiatry, demonstrating recognition within the psychiatric research community. While specific awards aren't mentioned in the provided materials, the consistent publication record in top-tier journals indicates professional recognition.
She actively collaborates with international research teams, particularly evident in the International Psychosis Epidemiology Consortium work. Her research methodology spans randomized controlled trials, cluster analysis of clinical data, and neuroimaging studies, showing methodological versatility. Her involvement in the HAMLETT trial as a contributor further demonstrates engagement with pragmatic clinical research addressing antipsychotic medication management in first-episode psychosis.
